CAR T cells produced in vivo to treat cardiac injury
Open accessThe DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
Making CAR T cells in vivo: Cardiac fibrosis is the stiffening and scarring of heart tissue and can be fatal. Rurik et al . designed an immunotherapy strategy to generate transient chimeric antigen receptor (CAR) T cells that can recognize the fibrotic cells in the heart (see the Perspective by Gao and Chen). By injecting CD5-targeted lipid nanoparticles containing the messenger RNA (mRNA) instructions needed to reprogram T lymphocytes, the researchers were able to generate therapeutic CAR T cells entirely inside the body. Analysis of a mouse model of heart disease revealed that the approach was successful in reducing fibrosis and restoring cardiac function. The ability to produce CAR T cells in vivo using modified mRNA may have a number of therapeutic applications. —PNK
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“We used an Ang II/PE infusion model to study cardiac fibrosis which has inherent limitations3,4,7,39”
From Targeting immune–fibroblast cell communication in heart failure (2024) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Recent advances in CAR T-cell technology have provided a much needed breakthrough and indicated that selectively removing activated cardiac fibroblasts that express fibroblast activator protein (FAP) is sufficient to ameliorate fibrosis without impacting the structural integrity of the heart in preclinical mouse models 9,10 .”
From Targeting the Immune-Fibrosis Axis in Myocardial Infarction and Heart Failure (2022) · cites this paper as [10]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Recent studies have implicated a potential pathogenic role for FAP+ fibroblasts in mouse models of cardiac remodelling3,4.”
From Targeting immune–fibroblast cell communication in heart failure (2024) · cites this paper as [3]
The cited source says what the claim attributes to it.
In the citing paper
“LNPs and CAR-T cells have been combined for antifibrotic therapy in experimental heart fibrosis by administering LNPs that reprogram host lymphocytes into CAR-T cells in order to target cardiac myofibroblasts that express fibroblast activation peptide alpha (FAP) (129).”
From Found in translation—Fibrosis in metabolic dysfunction–associated steatohepatitis (MASH) (2023) · cites this paper as [129]
The cited source says what the claim attributes to it.
In the citing paper
“Recent studies have utilized chimeric antigen receptor (CAR) T cells to target FAP + fibroblasts in a mouse model of cardiac injury and shown improved cardiac function and diminished fibrosis 9,10 .”
From Targeting the Immune-Fibrosis Axis in Myocardial Infarction and Heart Failure (2022) · cites this paper as [10]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
mRNA vaccines — a new era in vaccinology
Pardi, N., Hogan, M. J., Porter, F. W., & Weissman, D. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.243 · Cited by 4,667
Self-citationKarikó, K., Buckstein, M., Ni, H., & Weissman, D. (2005) · Immunity · doi:10.1016/j.immuni.2005.06.008 · Cited by 2,728
Self-citationKalos, M., Levine, B. L., Porter, D. L., Katz, S., Grupp, S. A., Bagg, A., & June, C. H. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002842 · Cited by 2,388
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Self-citationFibrosis: from mechanisms to medicines
Henderson, N. C., Rieder, F., & Wynn, T. A. (2020) · Nature · doi:10.1038/s41586-020-2938-9 · Cited by 1,868
CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis
Gillmore, J. D., Gane, E., Taubel, J., Kao, J., Fontana, M., Maitland, M. L., Seitzer, J., O’Connell, D., Walsh, K. R., Wood, K., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107454 · Cited by 1,801
Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms
Akinc, A., Querbes, W., De, S., Qin, J., Frank-Kamenetsky, M., Jayaprakash, K. N., Jayaraman, M., Rajeev, K. G., Cantley, W. L., Dorkin, J. R., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2010.85 · Cited by 1,261
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
Self-citationFibroblast-specific TGF-β–Smad2/3 signaling underlies cardiac fibrosis
Khalil, H., Kanisicak, O., Prasad, V., Correll, R. N., Fu, X., Schips, T., Vagnozzi, R. J., Liu, R., Huynh, T., Lee, S.-J., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci94753 · Cited by 905
Sommermeyer, D., Hudecek, M., Kosasih, P. L., Gogishvili, T., Maloney, D. G., Turtle, C. J., & Riddell, S. R. (2016) · Leukemia · doi:10.1038/leu.2015.247 · Cited by 867
Cited by
Items 901–1,000 of 1,001
In vivo engineering chimeric antigen receptor immune cells with emerging nanotechnologies
Ren, H., Jin, Y., Huang, H., Wu, W., Dai, X., Fang, W. J., Qin, J., Li, H., & Zhao, P. (2024) · Nano Today · doi:10.1016/j.nantod.2024.102517 · Cited by 4
Engineering CRISPR for emerging therapeutic applications
Sun, X., & Liu, Z. (2024) · EngMedicine · doi:10.1016/j.engmed.2024.100035 · Cited by 4
Novel Therapeutic Strategies Targeting Fibroblasts to Improve Heart Disease
Li, Y. (2024) · Journal of Cellular Physiology · doi:10.1002/jcp.31504 · Cited by 4
Futures of CAR-T-therapy of solid tumors
Puchkov, I. A., Михайловна, К. Т., Parfenyuk, E. I., Kiseleva, Y. Y., Kaminskiy, V. V., Шишкин, А. М., Nikiruy, E. Y., & Bozhenko, K. V. (2024) · Immunologiya · doi:10.33029/1816-2134-2024-45-6-792-805 · Cited by 4
Zhu, C., Wang, F., Cheng, Z., Zhang, L. L., & Li, H. (2025) · Precision medicine and engineering. · doi:10.1016/j.preme.2025.100024 · Cited by 5
Gao, X. J. (2025) · Science · doi:10.1126/science.adw0397 · Cited by 4
Gao, Y., Zhou, Y., He, X., Lin, H., Fang, K., Hou, Q., Wang, H., Zhang, H., Zhang, Y., & Li, Y. (2025) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2025.2518634 · Cited by 4
Adjmi, M., Tse, I., & Zangi, L. (2025) · Cardiology Plus · doi:10.1097/cp9.0000000000000118 · Cited by 4
Immunomodulatory Delivery Materials for Tissue Repair
Est-Witte, S. E., Jain, M., Ben‐Akiva, E., Yang, J., Warren, T., Tzeng, S. Y., & Green, J. J. (2025) · Advanced Healthcare Materials · doi:10.1002/adhm.202501400 · Cited by 4
Programmable macromolecule delivery via engineered trogocytosis
Chen, X., Situ, Y., Yang, Y., Lyu, L., Han, M., Magni, L., Fu, M. L., Deng, B., Wang, S., & Qi, L. S. (2026) · Nature Cell Biology · doi:10.1038/s41556-026-01920-0 · Cited by 6
Racing CARs to veterinary immuno-oncology
Cockey, J. R., & Leifer, C. A. (2023) · Frontiers in Veterinary Science · doi:10.3389/fvets.2023.1130182 · Cited by 6
Wang, F., Li, P., Yan, X., Yue, A., Xu, J., Shao, Y., Zhang, K., Zhang, Q., Li, Y., & Sun, K. (2025) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2025.119920 · Cited by 6
A New Approach to In Vivo Transformation of Killer T Cells
Rodriguez, N., Hofmann, C., Yang, O. O., & Gelbart, W. M. (2025) · Journal of Molecular Biology · doi:10.1016/j.jmb.2025.169369 · Cited by 4
Muralidharan, K., Agarwal, D., Naji, A., & Bhoj, V. G. (2022) · The Journal of Immunology · doi:10.4049/jimmunol.2200542 · Cited by 4
The race to supercharge cancer-fighting T cells
Ledford, H. K. (2023) · Nature · doi:10.1038/d41586-023-00177-z · Cited by 4
Research progress in mRNA drug modification and delivery systems
Zhou, Z., & Li, X. (2023) · Journal of Zhejiang University (Medical Sciences) · doi:10.3724/zdxbyxb-2023-0101 · Cited by 8
Gao, H., Wang, X., Gan, H., Li, M., Shi, J., & Guo, Y. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e31198 · Cited by 4
Fitzgerald, A. A., Maynard, R. E., Davis-Marcisak, E. F., Nasir, A., Glasgow, E. F., Jablonski, S. A., der Veken, P. V., Pearson, G. W., Eisman, S. E., Mace, E. M., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.02.03.429622 · Cited by 4
CRISPR comes a-knock-in to reprogram antibodies in vivo
Hartweger, H., & Nussenzweig, M. C. (2022) · Nature Biotechnology · doi:10.1038/s41587-022-01299-x · Cited by 4
An insight into the use of CAR T-cell as a novel immunotherapy, to heal burn wounds
Moradi, S., Faraji, N., Farzin, M., & haghi, S. E. (2023) · Burns · doi:10.1016/j.burns.2022.12.020 · Cited by 4
Engineering immunotherapy from within
Peche, V. S., & Gottschalk, S. M. (2025) · Science · doi:10.1126/science.ady7928 · Cited by 4
Regenerative Engineering: Evolution and Its Modern Significance
Shi, Y., Zhang, L., Chen, M., Calle, E. A., & Langer, R. (2025) · Regenerative Engineering and Translational Medicine · doi:10.1007/s40883-025-00498-7 · Cited by 4
Engineered CAR-T cells: An immunotherapeutic approach for cancer treatment and beyond
Khodke, P., & Kumbhar, B. V. (2024) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2023.12.001 · Cited by 4
CAR T therapy from haematological malignancies to aging‐related diseases: An ever‐expanding universe
Ramoni, D., Montecucco, F., & Carbone, F. (2024) · European Journal of Clinical Investigation · doi:10.1111/eci.14203 · Cited by 3
CARs pick up another passenger: Organ transplantation
Papadaki, G. F., Li, Y., Monos, D. S., & Bhoj, V. G. (2024) · Human Immunology · doi:10.1016/j.humimm.2024.111180 · Cited by 3
Leveraging Vector-Based Gene Disruptions to Enhance CAR T-Cell Effectiveness
de Oliveira, B. C., Bari, S. M. N., & Melenhorst, J. J. (2025) · Cancers · doi:10.3390/cancers17030383 · Cited by 5
Cytotransducers for Visualization of Spatiotemporal Intercellular Communication
Kimura, N., Yamanishi, Y., & Sakuma, S. (2025) · Small · doi:10.1002/smll.202503749 · Cited by 3
Homedan, A., Pandya, D. N., Schnicker, N., & Wadas, T. J. (2025) · EJNMMI Radiopharmacy and Chemistry · doi:10.1186/s41181-025-00356-5 · Cited by 3
CSPG4.CAR-T Cells Modulate Extracellular Matrix Remodeling in DMD Cardiomyopathy
Ceraolo, M. G., Milan, M., Fratini, N., Viganò, R., Bousselmi, S., Soluri, A., Pesce, E., Mauri, P., Ciuffreda, G., Landoni, E., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26146590 · Cited by 3
Yan, Y., Luo, Z., Hu, X., Ou, M., Huang, M., Ni, X. F., Chen, H., & Ding, Y. (2025) · Advanced Materials · doi:10.1002/adma.202503139 · Cited by 3
Trogocytosis at crossroads: Navigating the duality in tumor-immune cell interactions
Yang, X. L., Huang, X., Chen, Z., Zhang, W., Liu, O., Wu, J., & Yan, F. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189431 · Cited by 6
Zahedipour, F., Gol, T. M., Wisser, S., Ramesh, A., Ureña-Bailén, G., Jaafari, M. R., & Mezger, M. (2025) · Current Research in Translational Medicine · doi:10.1016/j.retram.2025.103545 · Cited by 7
Immuno‐Packed T‐Cell‐Fusogenic Liposome Empowers Adoptive T Cell Therapy for Solid Tumor Treatment
Zheng, C., Yi, K., Du, Y., Zhong, Q., Kong, H., Wang, H., Ju, E., Lao, Y., Xie, X., Yao, H., et al. (2025) · Advanced Materials · doi:10.1002/adma.202510842 · Cited by 3
Feeder-free advances in T cell development and therapy
Zhu, E., Liu, Z., & Li, Y.-R. (2025) · Cell Biomaterials · doi:10.1016/j.celbio.2025.100244 · Cited by 3
Chimeric antigen receptor-based cellular therapy for T-cell malignancies
Li, S., Li, Y., Hui, M. Y., Rashid, A., Tan, H. K., Chan, S., Chan, W. Y. K., Lam, K. S., Tu, W., & Leung, W. H. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.105044 · Cited by 3
Chen, H., Zhang, J., Huang, J., Wu, Z., Tang, L., Tian, Y., Gao, S., Huang, S., Cao, J., Chen, J., et al. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-07470-7 · Cited by 4
Luong, D., Martel, N., Rae, J., Lo, H. P., Lim, Y., Wu, Y., McMahon, K., Sun, H., Fletcher, N. L., Thurecht, K. J., et al. (2025) · ACS Nano · doi:10.1021/acsnano.5c11452 · Cited by 3
Qian, H., He, Y., Deng, C.-Q., Ao-di, W., Ma, Y.-X., Zhuang, H., Chen, S., Li, Y., Chen, S., Zhang, X.-W., et al. (2026) · Acta Pharmacologica Sinica · doi:10.1038/s41401-025-01680-x · Cited by 3
Zong, Y., Wang, Y., Lin, Y., Li, Q., Li, M., Ren, H., Wang, X., Ma, Q., Yu, X., Hu, R., et al. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2026.01.002 · Cited by 4
Engineering Immune Cell to Counteract Aging and Aging‐Associated Diseases
Guo, J., Lei, L., Jin, Y., Su, L., Cui, S., & Shi, L. (2026) · Advanced Science · doi:10.1002/advs.202521776 · Cited by 3
You, T., Zhang, Y., Su, H., Wang, N., Zhang, X., Anwaier, S., Long, X. L., Han, L., Wu, Y., Liang, J., et al. (2026) · Bioactive Materials · doi:10.1016/j.bioactmat.2026.01.041 · Cited by 4
Advances in the Development of Lipid Nanoparticles for mRNA Delivery
Wang, X., Xu, L., Lan, Z., Hui, Y., Liu, Y., Yang, G., & Zhao, C. (2026) · Small Structures · doi:10.1002/sstr.202500568 · Cited by 3
Engineering viral vectors for in vivo CAR-T generation: Advances, challenges, and opportunities
Yang, P., Ma, Z., Liu, G., Shen, Y., Bai, Z., Zheng, S., & Xu, Z. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105209 · Cited by 4
Shao, M.-Q., Ya-nan, T., Shi, Y., Wu, L., Zhou, R., Zhang, J.-X., & Chen, S.-L. (2026) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2026.217670 · Cited by 3
Tissue‐specific gene delivery approaches
Nasr, S. S., Cheema, Y., Stern, A., Tabah, O., Poore, S., & Duncan, G. A. (2026) · Bioengineering & Translational Medicine · doi:10.1002/btm2.70125 · Cited by 4
Molecular imaging of lymphatic organs provides prognostic value after acute myocardial infarction
Reiter, T., Dörrler, A.-L., Hasenauer, N., Serfling, S. E., Higuchi, T., Kraus, N. A., Bauer, W. R., Hochholzer, W., Ramos, G., Samnick, S., et al. (2026) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-026-07809-2 · Cited by 3
A targeting lentiviral vector for generation of CAR-T cells in vivo
Tuerxunyiming, M., Yin, J. M., Zhu, P., Liu, M., Fu, Z., & Zhao, Q. (2026) · Scientific Reports · doi:10.1038/s41598-025-17342-1 · Cited by 3
Shen, J., Peng, J. I. N., Liang, Y., Zhu, J., Xiang, R., Li, Z., Zhu, H., Li, X., Zhang, Y., Wang, W., et al. (2026) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-026-03689-4 · Cited by 3
Non-viral and mRNA-based strategies for next-generation CAR-T cell therapy
Wang, T., Jin, F., Xing, W., & Yu, S. (2026) · Pathology - Research and Practice · doi:10.1016/j.prp.2026.156455 · Cited by 3
Cardiac fibroblast heterogeneity in cardiac fibrosis implication for cell-type-specific treatment
Gu, K., Song, D., & Chen, J. H. (2026) · Frontiers in Physiology · doi:10.3389/fphys.2026.1740147 · Cited by 3
Memory T cell aging and rejuvenation
Adamo, S., Rurik, J. G., Gustafson, C. E., & Buggert, M. (2026) · Immunity · doi:10.1016/j.immuni.2026.02.018 · Cited by 6
Self-citationXu, Z., Jolly, K. J., Sankara, C. S., Mi, K., Canchola, A., Feng, H., Gillen, O. P., Heiden, K. D., Basso, K. B. G., Chou, W., et al. (2026) · Biomaterials · doi:10.1016/j.biomaterials.2026.124223 · Cited by 4
Kochs, T., Nath, P., Chen, A. J., Romee, R., & Maia, A. (2026) · Advanced Science · doi:10.1002/advs.75326 · Cited by 4
Nanotechnology-enhanced CAR-T therapy strategies in cancer, aging, and autoimmune diseases
Li, H., Li, J., Liu, X. D., Wei, X., Zeng, X., Wang, Q. Y., Han, Y., Huang, H., & Qian, P. (2026) · Journal of Hematology & Oncology · doi:10.1186/s13045-026-01805-7 · Cited by 4
Qu, F., Fosu, K., Wagner, A. A., Dhanasinghe, J. C., Dyba, A., Liu, Y.-K., Dick, J. E., Tran, N. T., & Thompson, D. H. (2026) · ACS Nano · doi:10.1021/acsnano.5c21719 · Cited by 3
Polypeptide-engineered lipid nanoparticles for mRNA delivery with limited immunogenicity
Zeng, J., Zhang, Y., Zhao, G., Seow, B. Y. L., Balakrishnan, N., Goh, J. H., & Yang, Y. Y. (2026) · Nature Communications · doi:10.1038/s41467-026-73698-6 · Cited by 7
Huang, X., Hao, J., Wang, S., Deng, B., Wang, P., Zhao, Q., Liu, H., & Wang, J. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2534673123 · Cited by 4
Sharma, S. R. K., Saha, S., Arora, S., Ahlawa, Y. K., Sheoran, S., Mukherjee, S., Sinha, A., Chaudhary, K., & Gosipatala, S. B. (2026) · Disease and Therapeutics · doi:10.1016/j.dist.2026.100012 · Cited by 3
The evolving role of cytokines for CAR-T cell manufacturing and beyond
Guaza-Lasheras, M., Nimmerfroh, J., Schwarz, D., de Gruijl, T. D., Hartmann, J., Klein, C., Laubli, H. P., Lotem, M., Mittelstaet, J., Paget, C., et al. (2026) · Nature Biomedical Engineering · doi:10.1038/s41551-026-01703-w · Cited by 3
Delivery Systems for Therapeutic Genome Editing: Challenges, Innovations, and Future Perspectives
Yang, M., Song, Y., Wang, Z., Chao, K., Li, L., Zhang, X., Duan, X., Yu, C., Xue, R., & Zhao, J. (2026) · MedComm · doi:10.1002/mco2.70791 · Cited by 5
Self-citationLi, Y., Song, W., Huan, C., Xu, K., Sun, J., Zhen, X., Ouyang, H., Tang, H., Fan, Q., Zhi, W., et al. (2026) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2026.109089 · Cited by 3
Li, Y., Luo, R., Li, Y., Liu, Z., Duan, X., Qin, S., He, Z., & Liu, S. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119888 · Cited by 3
Structural features of sensory two component systems: a synthetic biology perspective
Nieves, M., Buschiazzo, A., & Trajtenberg, F. (2023) · Biochemical Journal · doi:10.1042/bcj20210798 · Cited by 3
Präzisionsmedizin vertieft die personalisierte Medizin in der Kardiologie
Hasenfuss, G. P., Schuster, A., Bergau, L., & Toischer, K. (2024) · Die Innere Medizin · doi:10.1007/s00108-024-01663-w · Cited by 3
Potential therapeutic targets of fibrosis in inflammatory rheumatic diseases
Jiang, S., Desmarais, J., Chu, C., & Zhu, J. (2024) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2024.101945 · Cited by 3
Precision Genetic Therapies: Balancing Risk and Benefit in Patients with Heart Failure
Johnston, J. R., & ADLER, E. D. (2024) · Current Cardiology Reports · doi:10.1007/s11886-024-02096-5 · Cited by 4
Intercellular Transfer of Immune Regulatory Molecules Via Trogocytosis
Park, S., Kim, J., & Shin, J. H. (2024) · Results and problems in cell differentiation · doi:10.1007/978-3-031-62036-2_6 · Cited by 3
Zhang, R., Si, G., Li, J., Li, X., Cui, H., & Pan, S. (2024) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.2024.j116 · Cited by 3
Zhong, G., Luo, Y., Wang, M., Yu, Z., Zou, X., Wang, G., Chen, F., & Yu, Y. (2025) · Engineered Regeneration · doi:10.1016/j.engreg.2025.03.002 · Cited by 3
The Immunopathophysiology of Organ Fibrosis: from Mechanisms to Immunotherapies
He, J., Ferapontova, I., Chen, J., Ito, M., Isagawa, T., Takeda, N., & Stockmann, C. (2025) · Physiology · doi:10.1152/physiol.00063.2024 · Cited by 5
Crist, R. M., Barenholz, Y., Cern, A., Clark, K. N., Cullis, P. R., Dean, C. A., Desai, N., Ferrari, M., Germain, M., Giacomantonio, C. A., et al. (2025) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.70020 · Cited by 5
Pioneering next-generation mRNA therapeutics through molecular engineering and delivery optimization
Qi, L., Li, Z., Feng, Z., Liu, J., & Chen, X. S. (2025) · Materials Today · doi:10.1016/j.mattod.2025.08.023 · Cited by 3
CAR-T Immunotherapy to Beat Solid Tumors: From Challenges to Improvements
Li, C., Liu, Z., & Zhou, Y. (2022) · Highlights in Science Engineering and Technology · doi:10.54097/hset.v8i.1110 · Cited by 3
Critical point for membrane bilayer formation
Gershfeld, N. L., & Nossal, R. (2023) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2022.184116 · Cited by 3
Zhang, G., Deng, L., Lu, H., & Zhang, W. (2023) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-023-01670-1 · Cited by 4
The 14th International Podocyte Conference 2023: from podocyte biology to glomerular medicine
Koehler, S., Hengel, F. E., Dumoulin, B., Damashek, L. J., Holzman, L. B., Suszták, K., & Huber, T. B. (2024) · Kidney International · doi:10.1016/j.kint.2024.01.042 · Cited by 3
Al-Janabi, I. I. (2024) · Al-Rafidain Journal of Medical Sciences · doi:10.54133/ajms.v6i2.726 · Cited by 3
Standards and Metrology for Viral Vectors as Molecular Tools: Outcomes from a CCQM Workshop
Campbell, J. J., Almond, N. M., Bae, Y.-K., Bhuller, R. K., Briones, A., Cho, S., Cleveland, M. H., Cleveland, T. E., Galaway, F., He, H., et al. (2024) · Biologics · doi:10.3390/biologics4020013 · Cited by 3
Immunotherapy in the Context of Aortic Valve Diseases
Bartoli‐Leonard, F., Pennel, T. C., & Caputo, M. (2024) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-024-07608-7 · Cited by 3
Leveraging microRNAs for cellular therapy
Hasiuk, M., Dölz, M., Marone, R., & Jeker, L. T. (2023) · Immunology Letters · doi:10.1016/j.imlet.2023.08.005 · Cited by 3
LINKing signaling domains to enhance CAR T cells
Bucher, P., & Feucht, J. (2023) · Nature Cancer · doi:10.1038/s43018-023-00538-7 · Cited by 3
Nanomedicine Approaches for In Vivo Cancer Immunotherapy
Hofstraat, S. R. J., Anbergen, T., & van der Meel, R. (2023) · Nanomedicine · doi:10.2217/nnm-2023-0230 · Cited by 3
Self-amplifying RNA-based CAR T cell therapy with enhanced duration and multi-genic logic functionsPreprint
Gu, Y., Choi, J., Mutha, D., Wu, C., Ganem, N. J., Grinstaff, M. W., & Wong, W. W. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.02.18.706661 · Cited by 3
Programmable Lipid Nanoparticle Targeting via Corona EngineeringPreprint
Kayabölen, A., Schmitt-Ulms, C., Elsener, A., Ferraresso, F., Donnelly, K. A., Nan, A. X., Harris, I., Sgrizzi, S. R., Anwer, A., Nuccio, S. P., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.02.27.708523 · Cited by 3
Cardiotoxicities of Chimeric Antigen Receptor T-Cell Therapy and Bispecific T-Cell Antibodies
Qamer, S. Z., Miraglia, G. M., Granville, M. J., Finkelstein, A., Okin, E., & Mahmood, S. S. (2024) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-024-01041-7 · Cited by 2
Advances in Cardiac Fibrosis Research and Treatment Development
Kim, Y. S., & Ahn, Y. (2025) · Journal of Cardiovascular Intervention · doi:10.54912/jci.2024.0036 · Cited by 3
Role of Perturbations of Epigenetic Processes in Cardiac Hypertrophy and Fibrotic Scarring
Duvey, B. K., Sharma, D., Mittal, V., & Sharma, A. (2025) · Current Cardiology Reviews · doi:10.2174/011573403x354902250708134633 · Cited by 2
Enhancing therapeutic potential of cellular hitchhiking through bioorthogonal chemistry
Jia, J., Zhang, M., Tong, A., Fang, T., Ma, X., Gao, Y., Zhang, J., Wang, D., & Li, J. (2025) · Chemical Engineering Journal · doi:10.1016/j.cej.2025.167492 · Cited by 2
Xiang, S., Shan, Y., Shi-hong, X., Wang, J., Luo, M., Zhou, J., & Chen, Q. (2025) · Advanced Science · doi:10.1002/advs.202501820 · Cited by 2
From bench to bloodstream: Lipid nanoparticles drive on-demand CAR-T cells
June, C. H., & Aghajanian, H. K. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.08.015 · Cited by 2
Self-citationThe Coming of Age of Gene Therapy for the Treatment of Human Diseases: A Regulatory Perspective
Rodríguez, L., de Felipe, P., Martín, R., Martínez, J., Ordóñez, D., Rojo, S., Martínez, J. F., Rincón, E., Cejalvo, T., Izquierdo, I., et al. (2025) · Human Gene Therapy · doi:10.1177/10430342251372047 · Cited by 2
Batho, C. A. P., Hudson, J. E., & Wilson, C. H. (2025) · Biochemical Society Transactions · doi:10.1042/bst20243001 · Cited by 3
Engineered RNA Devices for In Vivo Targeted Therapeutics via Advanced Delivery Systems
Luo, W., Liu, X., Han, Y., Duan, Y., Yu, C., Kong, N., & Xie, T. (2025) · Aggregate · doi:10.1002/agt2.70191 · Cited by 2
Regulatory T Cells and Nanomaterials: Dual Perspectives in Therapeutics and Immunomodulation
Chen, Y. H., Huang, H., Wang, X., Yu, X., Huang, Z., Jin, Z., Chen, C., Chen, Y., Blazar, B. R., Xu, Y., et al. (2025) · Small Science · doi:10.1002/smsc.202500481 · Cited by 2
pH-Isomerizable Acylhydrazone-Based Ionizable Lipids for Spleen-Targeted mRNA Vaccines
Deng, X., Li, Y., Zhu, X., Du, Y., Chi, H., Cheng, M., Wang, Y., An, K., & Zhang, P. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.5c16121 · Cited by 3
Broadening CAR-T access: lessons from real-world implementation of talicabtagene autoleucel in India
Purwar, A., Jain, H., & Kumar, S. (2025) · Blood Immunology & Cellular Therapy · doi:10.1016/j.bict.2025.100026 · Cited by 2
Integrating CAR-T cells with other immunotherapies for improved efficacy in cancer patients
Singh, G., Kumari, L., Katoch, D., Sood, A., Thakur, N., Singh, K., & Kumar, U. (2025) · Current Research in Translational Medicine · doi:10.1016/j.retram.2025.103562 · Cited by 2
Zhang, M., Pan, X., Li, J., & Wang, H. (2026) · Chinese Chemical Letters · doi:10.1016/j.cclet.2026.112358 · Cited by 3
From quantum computing to mRNA therapeutics: seven technologies to watch in 2026
Eisenstein, M. S. (2026) · Nature · doi:10.1038/d41586-026-00188-6 · Cited by 2
Tiny tools closing the gap: nanobodies in research and therapy
Abdellatif, M., Rajurkar, J., & Leonhardt, H. (2026) · Function · doi:10.1152/function.107.2025 · Cited by 3
Metadata
- Authors
- Rurik, J. G., Tombácz, I., Yadegari, A., Méndez Fernández, P. O., Shewale, S. V., Li, L., Kimura, T., Soliman, O. Y., Papp, T. E., Tam, Y. K., Mui, B. L., Albelda, S. M., Puré, E., June, C. H., Aghajanian, H., Weissman, D., Parhiz, H., & Epstein, J. A.
- Affiliations
- University of Pennsylvania (US)
- Department of Cell and Developmental Biology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
- Acuitas Therapeutics (Canada) (CA)
- Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
- Corresponding author
- Tombácz, István
- Yadegari, Amir
- Aghajanian, Haig
- Weissman, Drew
- Parhiz, Hamideh
- Epstein, Jonathan A.
- ORCID
- Venue
- Science
- Published
- 2022-01-07
- Volume
- 375
- Issue
- 6576
- Pages
- 91-96
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC9983611
- OpenAlex
- W4206716689
- Cited by
- 1,400
- References
- 36
- Citations by year
- 2026: 375 · 2025: 348 · 2024: 312 · 2023: 215 · 2022: 148
- FWCI
- 106.97
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Heart, Lung, and Blood Institute (R01HL134839, R35HL140018)
- National Institute of Allergy and Infectious Diseases (R01AI124429, U19AI142596, P30AI045008)
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
- Keywords
- chimeric antigen receptor T cells, myocardial fibrosis, heart failure, lipid nanoparticles, mRNA delivery, antifibrotic therapy, trogocytosis, cardiac injury
- MeSH terms
- Receptors, Chimeric Antigen, Trogocytosis, Fibroblast Activation Protein Alpha, Animals, Fibroblasts, Fibrosis, Heart Diseases, Heart Failure, Humans, Liposomes, Male, Membrane Proteins, Mice, Inbred C57BL, Myocardium, Endopeptidases, RNA, Messenger, Spleen, T-Lymphocytes, Immunotherapy, Adoptive, CD5 Antigens, Adoptive Transfer, Mice, Nanoparticles, HEK293 Cells, Cell Engineering
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.